Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. (AGIO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AGIO · as of Mar 31, 2025
Ownership Breakdown
228
Institutional Holders
▼ 7 vs Q4
$1.76B
Total Inst. Value
▼ $203.56M vs Q4
59.47M
Shares Outstanding
freeFloat 93.68%
60.10M
13F Shares Held
▲ 254,249 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AGIO largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FARALLON CAPITAL MANAGEMENT LLC pharmaceutical preparations | 5.70M | 9.92% | 9.92% | $167.02B | May 15, 2025 | ▲ 26.0K |
VANGUARD GROUP INC pharmaceutical preparations | 5.60M | 9.75% | 9.75% | $164.21B | May 9, 2025 | ▼ 26.7K |
BLACKROCK, INC. pharmaceutical preparations | 5.11M | 8.89% | 8.89% | $149.69B | May 2, 2025 | ▲ 92.5K |
BELLEVUE GROUP AG pharmaceutical preparations | 3.52M | 6.12% | 6.12% | $102.99B | May 14, 2025 | — held |
STATE STREET CORP pharmaceutical preparations | 2.45M | 4.26% | 4.26% | $71.77B | May 15, 2025 | ▲ 297.2K |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 2.30M | 4.01% | 4.01% | $67.43B | May 14, 2025 | ▼ 122.2K |
ERSTE ASSET MANAGEMENT GMBH pharmaceutical preparations | 2.23M | 3.88% | 3.88% | $65.44B | May 14, 2025 | ▲ 220.0K |
COMMODORE CAPITAL LP pharmaceutical preparations | 2.19M | 3.80% | 3.80% | $64.02B | May 15, 2025 | NEW |
ARMISTICE CAPITAL, LLC pharmaceutical preparations | 2.05M | 3.56% | 3.56% | $60.01B | May 15, 2025 | ▼ 216.3K |
MACQUARIE GROUP LTD pharmaceutical preparations | 1.85M | 3.22% | 3.22% | $54.22B | Aug 14, 2025 | ▲ 165.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
25
Increased
+3.74M shares3
New Positions
first time holders19
Decreased
−1.72M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.02M
+3.74M / −1.72M
Net new holders
+9
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AGIO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
34
Buy transactions
41
Sell transactions
0.83
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Burns James William Chief Legal Officer | Apr 2, 2026 | Sale | 3,280 | $34.71 | $113.8K | 49.3K | Form 4 ↗ |
Gheuens Sarah Chief Medical Officer | Apr 2, 2026 | Sale | 2,940 | $34.71 | $102.0K | 80.3K | Form 4 ↗ |
Jones Cecilia Chief Financial Officer | Apr 2, 2026 | Sale | 3,141 | $34.71 | $109.0K | 55.0K | Form 4 ↗ |
Milanova Tsveta Chief Commercial Officer | Apr 2, 2026 | Sale | 3,262 | $34.71 | $113.2K | 46.8K | Form 4 ↗ |
Viswanadhan Krishnan Chief Corp Dev & Strategy | Apr 2, 2026 | Sale | 2,959 | $34.71 | $102.7K | 10.3K | Form 4 ↗ |
Goff Brian Chief Executive Officer | Apr 2, 2026 | Sale | 6,596 | $34.71 | $228.9K | 184.5K | Form 4 ↗ |
Goff Brian Chief Executive Officer | Apr 2, 2026 | Sale | 12,472 | $34.71 | $432.9K | 177.6K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Agios Pharmaceuticals, Inc. (AGIO) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 6.32%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Agios Pharmaceuticals, Inc. is FARALLON CAPITAL MANAGEMENT LLC, holding approximately 5.70 million shares — equal to 9.92% of outstanding shares — as of March 31, 2025.
A total of 228 institutional investors currently hold AGIO stock, with a combined institutional value of approximately $1.76 billion as of the most recent 13F filing period.
Frequently asked questions
AGIO ownershipAgios Pharmaceuticals, Inc. (AGIO) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is FARALLON CAPITAL MANAGEMENT LLC with a 9.92% stake. Company insiders hold 6.32%. Data sourced from SEC Form 13F as of March 31, 2025.